






# KRIBIOLISA™ Anti Ustekinumab (STELARA) ELISA

**REF** : KBI2014

Ver 1.2


**RUO**

Enzyme Immunoassay for the Quantitative Determination of Anti-Ustekinumab in human serum and plasma

<b>RUO</b>	<b>For Research Use</b>	<b>REF</b>	<b>Catalog Number</b>
	<b>Store At</b>	<b>LOT</b>	<b>Batch Code</b>
	<b>Manufactured By</b>		<b>Biological Risk</b>
	<b>Expiry Date</b>		<b>Consult Operating Instructions</b>

*For Research Use Only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.*

**REF** KBI2014

 96 tests

 **KRISHGEN BioSystems**

Unit Nos#318/319, Shah & Nahar,  
Off Dr E Moses Road, Worli, Mumbai 400018.  
Tel: 91 (22) 49198700 | Email: sales@krishgen.com  
<http://www.krishgen.com>

**Introduction:**


Ustekinumab is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. In two Phase III trials for moderate to severe psoriasis, the longest >76 weeks, ustekinumab was safe and effective. A third Phase III trial, ACCEPT, compared the efficacy and safety of ustekinumab with etanercept in the treatment of moderate to severe plaque psoriasis. This trial found a significantly higher clinical response with ustekinumab over the 12-week study period compared to high-dose etanercept. It also demonstrated the clinical benefit of ustekinumab among patients who failed to respond to etanercept. Ustekinumab is approved in Canada, Europe and the United States to treat moderate to severe plaque psoriasis. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Etanercept and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Ustekinumab and may be used for monitoring immunogenicity.

**Intended Use:**

The KRIBIOLISA™ Anti-Ustekinumab ELISA is used as an analytical tool for quantitative determination of Anti-Ustekinumab in human serum and plasma.

**Principle:**

The method employs the quantitative sandwich enzyme immunoassay technique. Ustekinumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Ustekinumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Ustekinumab is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Ustekinumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

**Materials Provided:**

Part	Description	Qty
Recombinant Ustekinumab Coated Microtiter Plate	96 well polystyrene microplate (12 strips of 8 wells) coated with Recombinant Ustekinumab	1 x 96 wells
Anti-Ustekinumab Standard	Lyophilized Anti-Ustekinumab Standard (concentrated – 1000 ng/ml)	2 vials
Ustekinumab:HRP Conjugate	Ustekinumab: HRP Conjugate prepared in buffer with protein stabilizer and preservatives 0.02% methylisothiazolone and 0.02% bromonitrodioxane.	12 ml
(1X) Sample Diluent	Buffered protein base with preservative thiomersol < 0.01%	2 x 50 ml
(1X) Standard Diluent	Buffered protein base with preservative thiomersol < 0.01% with 1:1000 dilution human serum	10 ml
(20X) Wash Buffer	20-fold concentrated solution of buffered surfactant with preservative thiomersol < 0.01%. May turn yellow over time.	25 ml
TMB Substrate	Stabilized Chromogen	12 ml
Stop Solution	0.73M Phosphoric Acid	12 ml
Instruction Manual		1 no

**Materials to be provided by the End-User:**

1. Microtiter Plate Reader able to measure absorbance at 450 nm.
2. Adjustable pipettes and multichannel pipettor to measure volumes ranging from 25µl to 1000µl
3. Deionized (DI) water
4. Wash bottle or automated microplate washer
5. Graph paper or software for data analysis
6. Timer
7. Absorbent Paper

**Handling/Storage:**

1. All reagents should be stored at 2°C to 8°C for stability.
2. All the reagents and wash solutions should be used within 12 months from manufacturing date.
3. Before using, bring all components to room temperature (18-25°C). Upon assay completion ensure all components of the kit are returned to appropriate storage conditions.
4. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

**Health Hazard Warnings:**

1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin.
2. For Research Use Only.

**Sample Preparation and Storage:**

Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at - 20°C.

For Cell Culture Supernatant – If necessary, centrifuge to remove debris prior to analysis. Samples can be stored at -20°C or -80°C. Avoid repeated freeze-thaw cycles.

**Preparation Before Use:**

Allow samples to reach room temperature prior to assay. Take care to agitate patient samples gently in order to ensure homogeneity.

Test Sample preparation - Samples have to be diluted 1:1000 (v/v), e.g. for 1:1000 (1 ul sample + 999 ul sample diluent) prior to assay. The samples may be kept at 2 - 8°C for up to three days. Long-term storage requires - 20°C.

**Reagent Preparation (all reagents should be diluted immediately prior to use):**

1. Label any aliquots made with the kit Lot No and Expiration date and store it at appropriate conditions mentioned.
2. Bring all reagents to Room temperature before use.
3. To make Wash Buffer (1X); dilute 25 ml of (20X) Wash Buffer in 475 ml of DI water.
4. **Standards Preparation:** Reconstitute the concentrated Standard lyophilized vial with 1 ml of Standard Diluent (1X) to obtain a concentration of 1000 ng/ml. Keep the vial for 15 mins with gentle agitation before making further dilutions. Dilute 640 ul of original **Standard (1000 ng/ml)** with 360 ul of Standard Diluent (1X) to generate a **640 ng/ml Standard Solution**. Prepare further **Standards** by serially diluting the Standard Solution as per the below table. Use the Standard Diluent(1X) as the Zero Standard (Standard No.0).

Standard Concentration	Standard Vial	Dilution Particulars
1000 ng/ml	Original Standard	Original Standard provided in the Kit + 1ml Standard Diluent (1X)
640 ng/ml	Standard No.7	640 ul Original Standard (1000 ng/ml) + 360 ul Standard Diluent (1X)
320 ng/ml	Standard No.6	500 ul Standard No.7 + 500 ul Standard Diluent (1X)
160 ng/ml	Standard No.5	500 ul Standard No.6 + 500 ul Standard Diluent (1X)
80 ng/ml	Standard No.4	500 ul Standard No.5 + 500 ul Standard Diluent (1X)
40 ng/ml	Standard No.3	500 ul Standard No.4 + 500 ul Standard Diluent (1X)
20 ng/ml	Standard No.2	500 ul Standard No.3 + 500 ul Standard Diluent (1X)
10 ng/ml	Standard No.1	500 ul Standard No.2 + 500 ul Standard Diluent (1X)
0 ng/ml	Standard No. 0	Only Standard Diluent (1X)

Use the Standards as soon as possible upon reconstitution. Discard balance standard after use.

#### Procedural Notes:

1. In order to achieve good assay reproducibility and sensitivity, proper washing of the plates to remove excess un-reacted reagents is essential.
2. High Dose Hook Effect may be observed in samples with very high concentrations of Anti-Ustekinumab. High Dose Hook Effect is due to excess of antibody for very high concentrations of Anti-Ustekinumab present in the sample. High Dose Hook effect is most likely encountered from samples early in the purification process. If Hook Effect is possible, the samples to be assayed should be diluted with a compatible diluent. Thus if the Anti-Ustekinumab concentration of the undiluted sample is less than the diluted sample, this may be indicative of the Hook Effect.
3. Avoid assay of Samples containing sodium azide ( $\text{NaN}_3$ ), as it could destroy the HRP activity resulting in under-estimation of the amount of Anti-Ustekinumab.
4. It is recommended that all Standards and Samples be assayed in duplicates.
5. Maintain a repetitive timing sequence from well to well for all the steps to ensure that the incubation timings are same for each well.
6. If the Substrate has a distinct blue color prior to use it may have been contaminated and use of such substrate can lead to compromisation of the sensitivity of the assay.
7. The plates should be read within 30 minutes after adding the Stop Solution.
8. Make a work list in order to identify the location of Standards and Samples.

#### Assay Procedure:

1. It is strongly recommended that all Standards and Samples be run in duplicates or triplicates. A standard curve is required for each assay. All steps must be performed at 37°C
2. Pipette **100 ul** of **Standards** or **diluted Samples** into the respective wells.
3. Cover the plate and incubate for 60 minutes at 37°C
4. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
5. Pipette **100 ul** of **Ustekinumab:HRP Conjugate** into each well.
6. Cover the plate and incubate for 60 minutes at 37°C
7. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
8. Add **100 ul** of **TMB Substrate** in each well.

9. Incubate the plate at 37°C for 30 minutes in dark. DO NOT SHAKE or else it may result in higher backgrounds and worse precision. Positive wells should turn bluish in color.
10. Pipette out **100 ul** of **Stop Solution**. Wells should turn from blue to yellow in color.
11. Read the absorbance at 450 nm with a microplate reader.

### Calculation of Results:

Determine the Mean Absorbance for each set of duplicate or triplicate Standards and Samples. Using Semi-Log graph paper, plot the average value (absorbance 450nm) of each standard on the Y-axis versus the corresponding concentration of the standards on the X-axis. Draw the best fit curve through the standard points. To determine the unknown Anti-Ustekinumab concentrations, find the unknown's Mean Absorbance value on the Y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the X-axis and read the Anti-Ustekinumab Concentration. If samples were diluted, multiply by the appropriate dilution factor. Software which is able to generate a cubic spline curve-fit is best recommended for automated results.

### Note:


It is recommended to repeat the assay at a different dilution factor in the following cases:

- If the sample absorbance value is below the first standard.
- If the absorbance value is equivalent or higher than the 640 ng/ml standard.

### Typical Data

Standard Concentration (ng/ml)	Abs A	Abs B	Mean Abs	Interpolated Concentration	% Interpolated Concentration against Actual Concentration
0	0.069	0.075	0.072	--	--
10	0.265	0.264	0.264	10.5	104.7
20	0.425	0.420	0.423	20.1	100.4
40	0.713	0.684	0.699	39.2	98.0
80	1.182	1.137	1.159	81.0	101.3
160	1.722	1.675	1.699	158.3	98.9
320	2.290	2.266	2.278	323.6	101.1
640	2.625	2.803	2.714	636.2	99.4

### Typical Graph



Abs= Absorbance at 450nm

### Quality Control:

It is recommended that for each laboratory assay appropriate quality control samples in each run to be used to ensure that all reagents and procedures are correct.

### Performance Characteristics of the Kit:

This kit has been validated as per EMA/FDA guidelines in line with ICH Code for Harmonization of Biological Assays.

### Sensitivity:

**Limit Of Detection:** It is defined as the lowest detectable concentration corresponding to a signal of Mean of '0' standard plus 2\* SD.

10 replicates of '0' standards were evaluated and the LOD was found to be less than 5 ng/ml

### Specificity:

The coating protein used for capture is Ustekinumab. The standard / calibrators used is Anti-Ustekinumab.

### Precision:

Precision is defined as the percent coefficient of variation (%CV) i.e. standard deviation divided by the mean and multiplied by 100. Assay precision was determined by both intra (n=5 assays) and inter assay (n=5 assays) reproducibility on two pools with low (10 ng/ml), medium (80 ng/ml) and high (640 ng/ml) concentrations. While actual precision may vary from laboratory to laboratory and technician to technician, it is recommended that all operators achieve precision below these design goals before reporting results.

Pool	Intra Assay %CV	Inter Assay %CV
Low	<10%	<10%
Medium	<5%	<5%
High	<5%	<5%

### Safety Precautions:

- **This kit is For Research Use only.** Follow the working instructions carefully.
- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.
- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed
  - Do not smoke, eat or drink while handling kit material
  - Always use protective gloves
  - Never pipette material by mouth
  - Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.



### References:

Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease

Y Morita, T Imai, S Bamba, K Takahashi... - Journal of ..., 2020 - Wiley Online Library

The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab

HY Chiu, TW Chu, YP Cheng, TF Tsai - PLoS One, 2015 - journals.plos.org

Clinical impact of antibodies against ustekinumab in psoriasis: an observational, cross-sectional, multicenter study

FC Loeff, T Tsakok, L Dijk, MH Hart... - Journal of Investigative ..., 2020 - Elsevier

Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn's Disease

Y Kwon, B Kang, ES Kim, YH Choe... - Therapeutic Drug ..., 2022 - ncbi.nlm.nih.gov

Comparison of serum concentrations of ustekinumab obtained by three commercial assays in patients with Crohn's disease

C Verdon, N Vande Castele, V Heron... - Journal of the ..., 2021 - academic.oup.com

Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

PL Martin, C Sachs, N Imai, H Tsusaki... - ... Research Part B ..., 2010 - Wiley Online Library

Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab


S Mojtahed Poor, T Ulshöfer, LA Gabriel... - Clinical & ..., 2019 - academic.oup.com

**SCHEMATIC ASSAY PROCEDURE**



1. Remove all components, 30 minutes before adding into the assay plate.




2. Avoid repeated cool-thaw of the components as there will be a loss of activity and this can affect the results.






3.  Pipette **100 ul Standards / diluted Samples** into each well.

4.  Cover plate and incubate for  at 37°C.



5.  Aspirate and wash wells 4 times with **Wash Buffer (1X)**.

6.  Pipette **100 ul Ustekinumab:HRP Conjugate** into each well.

7.  Cover plate and incubate for  at 37°C.

8.  Aspirate and wash wells 4 times with **Wash Buffer (1X)**.

9.  Pipette **100 ul TMB Substrate** into each well.

10.  Cover plate and incubate for  at 37°C.

11.  Pipette **100 ul Stop Solution** into each well.

12. Read absorbance at 450nm with a  microplate reader within  of stopping reaction.

### Typical Example of a Work List

Well #	Contents	Absorbance at 450nm	Mean Absorbance	ng/ml Anti-Ustekinumab (STELARA) equivalent
1A 2A	zero std zero std			
1B 2B	10 ng/ml 10 ng/ml			
1C 2C	20 ng/ml 20 ng/ml			
1D 2D	40 ng/ml 40 ng/ml			
1E 2E	80 ng/ml 80 ng/ml			
1F 2F	160 ng/ml 160 ng/ml			
1G 2G	320 ng/ml 320 ng/ml			
1H 2H	640 ng/ml 640 ng/ml			
3A 4A	Sample			
3B 4B	Sample			

### LIMITED WARRANTY

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non Krishgen made products or components. This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective Products in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.













Krishgen Biosystems. 2022

### **THANK YOU FOR USING KRISHGEN PRODUCT!**

KRISHGEN BIOSYSTEMS®, GENLISA®, DHARMAPLEX™, GENBULK™, GENLISA™, KRISHZYME®, KRISHGEN®, KRIBIOLISA®, KRISHPLEX®, TITANIUM®, QUALICHEK® are registered trademarks of KRISHGEN BIOSYSTEMS. ©KRISHGEN BIOSYSTEMS. ALL RIGHTS RESERVED.

KRISHGEN BIOSYSTEMS | OUR REAGENTS | YOUR RESEARCH |

## SYMBOLS KEY

	Recombinant Ustekinumab Coated Microtiter Plate (12x8 wells)
	Anti-Ustekinumab Standard, lyophilized
	Conjugate Horseradish Peroxidase
	(1X) Standard Diluent
	(1X) Sample Diluent
	(20X) Wash Buffer
	TMB Substrate
	Stop Solution
	Consult Instructions for Use
	Catalog Number
	Expiration Date
	Storage Temperature